"Hallucinogens" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs capable of inducing illusions, hallucinations, delusions, paranoid ideations, and other alterations of mood and thinking. Despite the name, the feature that distinguishes these agents from other classes of drugs is their capacity to induce states of altered perception, thought, and feeling that are not experienced otherwise.
| Descriptor ID |
D006213
|
| MeSH Number(s) |
D27.505.696.388 D27.505.954.427.700.372
|
| Concept/Terms |
Hallucinogens- Hallucinogens
- Psychotomimetic Agents
- Agents, Psychotomimetic
- Hallucinogenic Agents
- Agents, Hallucinogenic
- Hallucinogenic Substances
- Substances, Hallucinogenic
- Psychedelics
- Psychedelic Agents
- Agents, Psychedelic
- Hallucinogenic Drugs
- Drugs, Hallucinogenic
|
Below are MeSH descriptors whose meaning is more general than "Hallucinogens".
Below are MeSH descriptors whose meaning is more specific than "Hallucinogens".
This graph shows the total number of publications written about "Hallucinogens" by people in this website by year, and whether "Hallucinogens" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 1999 | 1 | 0 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 5 | 0 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 0 | 1 |
| 2014 | 4 | 1 | 5 |
| 2015 | 2 | 0 | 2 |
| 2016 | 3 | 0 | 3 |
| 2017 | 2 | 0 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 3 | 1 | 4 |
| 2020 | 1 | 0 | 1 |
| 2021 | 4 | 0 | 4 |
| 2022 | 5 | 0 | 5 |
| 2023 | 5 | 0 | 5 |
| 2024 | 4 | 2 | 6 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hallucinogens" by people in Profiles.
-
Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review. JAMA Psychiatry. 2026 Jul 01; 83(7):755-769.
-
An Open-Label Study of Single-Dose Psilocybin for Borderline Personality Disorder With Co-Occurring Major Depressive Disorder. Clin Neuropharmacol. 2026 Jul-Aug 01; 49(4):163-169.
-
The empathogen 3,4-methylenedioxymethamphetamine, but not methamphetamine, increases feelings of global trust. J Psychopharmacol. 2026 Sep; 40(9):1361-1367.
-
Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities? Dialogues Clin Neurosci. 2025 12; 27(1):1-12.
-
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management. Curr Pain Headache Rep. 2025 Jan 07; 29(1):15.
-
Developing an Ethics and Policy Framework for Psychedelic Clinical Care: A Consensus Statement. JAMA Netw Open. 2024 06 03; 7(6):e2414650.
-
Psychedelics in Medicine: Can Evidence Keep Up With Enthusiasm? Biol Psychiatry Cogn Neurosci Neuroimaging. 2024 May; 9(5):460-461.
-
The 3,4-methylenedioxymethamphetamine enhances early visual processing for salient socio-emotional stimuli. Eur J Neurosci. 2024 06; 59(12):3224-3235.
-
Neural complexity is increased after low doses of LSD, but not moderate to high doses of oral THC or methamphetamine. Neuropsychopharmacology. 2024 Jun; 49(7):1120-1128.
-
MDMA enhances positive affective responses to social feedback. J Psychopharmacol. 2024 03; 38(3):297-304.